Effector mechanisms in low-dose streptozotocin-induced diabetes.
about
Current status and patent prospective of animal models in diabetic researchAltered Macrophage and Dendritic Cell Response in Mif-/- Mice Reveals a Role of Mif for Inflammatory-Th1 Response in Type 1 DiabetesThe unique hypusine modification of eIF5A promotes islet beta cell inflammation and dysfunction in mice.Antidiabetic and renoprotective effects of the chloroform extract of Terminalia chebula Retz. seeds in streptozotocin-induced diabetic rats.Transgenic expression of Hsc70 in pancreatic islets enhances autoimmune diabetes in response to beta cell damageThe use of animal models in diabetes research.Minireview: 12-Lipoxygenase and Islet β-Cell Dysfunction in Diabetes.Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease.Polyphenols isolated from Broussonetia kazinoki prevent cytokine-induced β-cell damage and the development of type 1 diabetesAntidiabetic Activity of Ruellia tuberosa L., Role of α-Amylase Inhibitor: In Silico, In Vitro, and In Vivo Approaches.Protein-tyrosine phosphatase 1B expression is induced by inflammation in vivo.Synergy Between Gαz Deficiency and GLP-1 Analog Treatment in Preserving Functional β-Cell Mass in Experimental Diabetes.Mechanisms and outcomes of drug- and toxicant-induced liver toxicity in diabetes.Vitamin D and human health: lessons from vitamin D receptor null mice.Detection of islet β-cell death in vivo by multiplex PCR analysis of differentially methylated DNA.Mesenchymal progenitors in osteopenias of diverse pathologies: differential characteristics in the common shift from osteoblastogenesis to adipogenesisExpression of the NH(2)-terminal fragment of RasGAP in pancreatic beta-cells increases their resistance to stresses and protects mice from diabetes.Protective effects of polyamine depletion in mouse models of type 1 diabetes: implications for therapy.Influence of acute and chronic streptozotocin-induced diabetes on the rat tendon extracellular matrix and mechanical properties.Pharmacological application of carbon monoxide ameliorates islet-directed autoimmunity in mice via anti-inflammatory and anti-apoptotic effects.Hypoglycemic activity of C-glycosyl flavonoid from Enicostemma hyssopifolium.The effects of electromagnetic pulses (EMP) on the bioactivity of insulin and a preliminary study of mechanism.High beta-cell mass prevents streptozotocin-induced diabetes in thioredoxin-interacting protein-deficient mice.Is There a Role for Bioactive Lipids in the Pathobiology of Diabetes Mellitus?Critical roles of Bim in T cell activation and T cell-mediated autoimmune inflammation in mice.Indomethacin reverses decreased hippocampal cell proliferation in streptozotocin-induced diabetic mice.DsAAV8-mediated expression of glucagon-like peptide-1 in pancreatic beta-cells ameliorates streptozotocin-induced diabetes.Pharmacological characterization of the cardiovascular responses elicited by kinin B(1) and B(2) receptor agonists in the spinal cord of streptozotocin-diabetic rats.Diabetes-induced changes in responsiveness of rat bladder and vas deferens to peptides in vitro: susceptibility to reversal by insulin.Preventative effects of the flowers of Inula britannica on autoimmune diabetes in C57BL/KsJ mice induced by multiple low doses of streptozotocin.Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil.beta cell protecting and immunomodulatory activities of Paecilomyces Hepiali Chen mycelium in STZ induced T1DM mice.T Cell-Mediated Beta Cell Destruction: Autoimmunity and Alloimmunity in the Context of Type 1 Diabetes.Persistence of STAT-1 inhibition and induction of cytokine resistance in pancreatic β cells treated with St John's wort and its component hyperforin.Bacille Calmette-Guérin/DNAhsp65 prime-boost is protective against diabetes in non-obese diabetic mice but not in the streptozotocin model of type 1 diabetes.Wdr13 and streptozotocin-induced diabetesLeflunomide protects mice from multiple low dose streptozotocin (MLD-SZ)-induced insulitis and diabetes
P2860
Q26799371-4F2CA8B1-171F-4EE0-A352-4120090FEA1FQ27349718-E30D0E0E-49CB-4608-8E00-D41C140AD874Q30435990-EF226A60-A03F-4522-B66C-3B9B1A74B18FQ30814386-E4DAA1D9-22EE-4F86-B352-6D1857685E98Q33737841-D0862AC7-CFEA-4D8A-BE60-343CBD077C72Q34255921-9694EDE0-49B3-42DF-9A0F-789D232C51E7Q34468392-44945B46-E8AE-4B0B-B493-56739655D308Q34542675-7C0A24E3-F9A6-4BC3-B18E-37C2D676900BQ35564309-E1218A7E-0E03-42A2-85AF-9DE6B2C40DF8Q35843855-FE08CB01-BBB6-46A4-8239-226C809864B9Q36662772-19DEF8F3-3FF9-4053-B27A-47CCA5DD79E1Q36859559-593C7C99-EB96-4A54-8F25-5E727505C5EAQ36871062-4ACF68FC-3149-4E79-B921-1B843BA9A402Q36973933-8D513679-B529-46F4-A254-61EBE15517B7Q37110915-987821A8-1ECA-4AB1-9A7C-17E770033D30Q37117479-7F3F640E-75F3-4A55-8254-9F59259F9C52Q37400767-3CAA60A1-30E3-41FD-8E14-25AF40A400DFQ37466399-0FC9BE5D-678B-47E9-909E-A04814BE016AQ38970414-E193F8A8-88B2-41F6-B182-8D4C86A2A875Q39027987-0E6D5C11-B191-4911-A3C3-472B08EBB206Q39578160-C273D0E6-F3E4-4D34-8D72-8A70F88B5CAAQ39752559-F620B4EB-F780-4657-B541-228D7260DC91Q39882740-E7D81D79-0FC6-4FED-9C68-B9B40F66C882Q41205365-E3BCCB05-B1D2-44BE-A474-08FA452E7EF2Q43119941-91C2DE80-B6A0-4CB2-906E-2A06532FC5B9Q43168195-755C0FAA-B8E7-497F-9702-905FA4089959Q43253089-F3F302C6-62DD-469A-86EF-80DE3FA06837Q43264456-5831A440-0987-4144-8EEC-708E9E36688EQ44003404-114A2F80-554C-427F-AECE-7FC104EA496DQ44060282-173EC352-0269-498A-85DD-EBEB62E2D832Q44091857-A60D7955-BA27-4C16-8BA9-FEBAC8E13D55Q45977194-F326BC02-AEF1-411F-A506-20ADF3AF1DC3Q47093542-B9A7B220-355A-4228-865E-B056076FBD50Q48223520-A3948192-6955-4DE8-AB10-E9B7DD00D52BQ50974904-966664CB-5980-4E81-8354-55B13D017D5EQ58106157-F9406DE6-C3E1-4250-BE50-551A889BB703Q59091288-532B88C6-9574-498D-8FEE-369AA879C727
P2860
Effector mechanisms in low-dose streptozotocin-induced diabetes.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Effector mechanisms in low-dose streptozotocin-induced diabetes.
@en
Effector mechanisms in low-dose streptozotocin-induced diabetes.
@nl
type
label
Effector mechanisms in low-dose streptozotocin-induced diabetes.
@en
Effector mechanisms in low-dose streptozotocin-induced diabetes.
@nl
prefLabel
Effector mechanisms in low-dose streptozotocin-induced diabetes.
@en
Effector mechanisms in low-dose streptozotocin-induced diabetes.
@nl
P2093
P356
P1433
P1476
Effector mechanisms in low-dose streptozotocin-induced diabetes.
@en
P2093
Stosić-Grujicić S
P304
P356
10.1155/1998/92198
P5008
P577
1998-01-01T00:00:00Z